TY - JOUR
TI - Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: Review of the literature
AU - Diamantopoulos, P.T.
AU - Athanasiadou, A.
AU - Papakostas, E.
AU - Gratsias, N.
AU - Georgiou, G.
AU - Mantzourani, M.
AU - Andreopoulos, G.
AU - Panagiotidis, P.
AU - Aessopos, A.
AU - Meletis, J.
AU - Viniou, N.
JO - Anti-Cancer Drug Design
PY - 2011
VL - 22
TODO - 9
SP - 944-947
PB - 
SN - 0266-9536, 1460-2148
TODO - 10.1097/CAD.0b013e3283486ca4
TODO - CD33 antigen;  CD34 antigen;  CD45 antigen;  cyclophosphamide;  cytarabine;  danazol;  etoposide;  Flt3 ligand;  hydroxyurea;  imatinib;  methylprednisolone;  microsomal aminopeptidase;  mitoxantrone;  platelet derived growth factor alpha receptor;  platelet derived growth factor beta receptor;  retinoblastoma protein;  transcription factor ETV6;  vincristine, acute granulocytic leukemia;  adult;  anemia;  blood analysis;  blood cell count;  bone marrow biopsy;  bone marrow examination;  cancer regression;  case report;  cytogenetics;  drug treatment failure;  drug withdrawal;  erythrocyte transfusion;  fatigue;  female;  fluorescence in situ hybridization;  gingiva bleeding;  granulocyte;  hematocrit;  hemolytic anemia;  human;  human cell;  human tissue;  karyotype;  karyotype 46,XX;  leukocyte;  leukopenia;  malaise;  mixed myelodysplastic myeloproliferative disease;  monotherapy;  physical examination;  polymerase chain reaction;  priority journal;  review;  thrombocytopenia;  treatment response;  upper gastrointestinal bleeding, Antineoplastic Agents;  Drug Resistance, Neoplasm;  Female;  Fusion Proteins, bcr-abl;  Humans;  Middle Aged;  Myelodysplastic Syndromes;  Myeloproliferative Disorders;  Piperazines;  Protein Kinase Inhibitors;  Pyrimidines;  Translocation, Genetic
TODO - The category of myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD) is a relatively new group of malignant hematologic diseases developed by the World Health Organization. These hematologic disorders lack the BCR/ABL fusion gene, although they can be associated with chromosomal translocations that involve genes encoding other protein kinases. Imatinib mesylate was recognized as a potent inhibitor of some of those kinases. We present a patient with a previously treated acute myeloid leukemia, who, after a 9-year-long remission, developed an MDS/MPD with normal karyotype, which initially responded to imatinib mesylate. Translocation t(12;13)(p12;q14) was detected after loss of response to imatinib treatment. Translocation t(12;13) is rare. It has been described in several hematologic malignancies including chronic myelomonocytic leukemia but not in MDS/MPD, previously described as Philadelphia-negative chronic myelogenous leukemia. Moreover, the correlation of this molecular abnormality with loss of efficacy of imatinib is unique in the literature. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
ER -